Abstract: Alzheimer ’s disease (AD) is a progressive neurodegenerative disorder marked by cognitive decline and memory loss. Its well-established pathological features include the presence of extracellular amyloid-beta (Aβ) plaques, intracellular tau-containing neurofibrillary tangles, and neuroinflammation (He et al., 2025). While AD research over the past few decades has focused mainly on genetic and protein-centric mechanisms, a growing body of evidence points to lipids as a critical, yet previously underappreciated dimension of AD pathology. Recent advances in lipidomics emphasize that lipid dysregulation is not merely a secondary disease phenomenon, but rather a central component, and potentially a driving force of AD progression. This perspective article highlights altered lipid metabolism as both a hallmark and a promising therapeutic target for AD.